ClinicalTrials.Veeva

Menu

Maxim® Knee Pop-Top® Tibia vs. Regular Maxim® Knee Tibia

Zimmer Biomet logo

Zimmer Biomet

Status

Terminated

Conditions

Traumatic Arthritis
Osteoarthritis
Rheumatoid Arthritis

Treatments

Device: Regular Maxim® Knee System
Device: Maxim® Knee System with Removable Molded Polyethylene Tibia

Study type

Interventional

Funder types

Industry

Identifiers

NCT00579059
62-U-007

Details and patient eligibility

About

The purpose of this prospective clinical data collection is to compare the outcomes of two different tibial bearings: the Maxim® Pop-Top® Tibia and Maxim® Modular Tibia.

Full description

The purpose of this prospective clinical data collection is to document and compare the performance and clinical outcomes between the Maxim® Knee System with Removable Molded Poly Tibia and the Maxim® Knee System with Modular Tibial Bearing as two treatment groups.

FDA has cleared these devices via Premarket Notification 510(k)'s K991753, K984623, K993159, K010027. The data gathered will be collated and used to provide feedback to designing engineers, support marketing efforts and answer potential questions from reimbursement agencies.

Enrollment

31 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Identical to the indications stated in the FDA approved labeling for the device (cleared in 510(k) K991753,

K984623, K993159, K010027). These indications are stated below:

  • Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.
  • Correction of varus, valgus, or posttraumatic deformity.
  • Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

Patient selection factors to be considered include:

  • need to obtain pain relief and improve function,
  • ability and willingness of the patient to follow instructions, including control of weight and activity level,
  • a good nutritional state of the patient,
  • the patient must have reached full skeletal maturity.
  • Porous coated knee joint replacement prostheses have not been approved for non-cemented applications in the United States.

Exclusion criteria

Identical to the contraindications stated in the FDA approved labeling for the device (cleared in 510(k) K991753, K984623, K993159, K010027's). These contraindications are stated below:

Absolute contraindications include:

  • infection,
  • sepsis
  • osteomyelitis.

Relative contraindications include:

  • uncooperative patient or patient with neurologic disorders who are incapable of following directions,
  • Osteoporosis,
  • metabolic disorders which may impair bone formation,
  • osteomalacia,
  • distant foci of infections which may spread to the implant site,
  • rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,
  • vascular insufficiency, muscular atrophy, neuromuscular disease,
  • incomplete or deficient soft tissue surrounding the knee.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

31 participants in 2 patient groups

1
Other group
Description:
Maxim® Pop-Top® Tibia
Treatment:
Device: Maxim® Knee System with Removable Molded Polyethylene Tibia
2
Other group
Description:
Maxim® Regular Tibia
Treatment:
Device: Regular Maxim® Knee System

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems